Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
Clinical Summary:
- Design/Population: This retrospective real-world study evaluated first-line chemoimmunotherapy versus platinum-based chemotherapy and non-platinum chemotherapy in patients with newly diagnosed extensive-stage small cell lung cancer.
- Key Outcomes: Chemoimmunotherapy significantly improved overall and progression-free survival compared with platinum-etoposide chemotherapy. Thoracic and brain-directed radiotherapy was associated with additional survival benefit, and immune-related adverse events correlated with improved outcomes.
- Clinical Relevance: These findings support chemoimmunotherapy as the preferred first line approach for extensive-stage small cell lung cancer and suggest that consolidative radiotherapy may further improve survival.
Real-world data from a large retrospective cohort study demonstrated that first-line chemoimmunotherapy significantly improved survival compared with chemotherapy alone among patients with extensive-stage small cell lung cancer (ES-SCLC).
“Phase 3 studies have shown significantly improved overall survival (OS) with the addition of PD-(L) 1 inhibitors to platinum-based chemotherapy, establishing chemoimmunotherapy as the new first-line standard,” stated Kyriaki Dimitriou, MD, Heidelberg University Hospital, Heidelberg, Germany, and coauthors. “This study investigates the real-world efficacy of [chemoimmunotherapy] compared to alternative first-line regimens in patients with ES-SCLC.”
In this study, researchers evaluated data from 904 patients with newly diagnosed ES-SCLC treated between 2010 and 2022. Patients received first-line chemoimmunotherapy (n = 203), platinum-based chemotherapy (n = 530), or non-platinum chemotherapy (n = 171). The primary end points were progression-free survival (PFS) and OS. Secondary end points included the impact of baseline brain metastases (30.9%), thoracic and brain radiotherapy, and immune-related adverse events.
At analysis, median OS was 10.2 months with chemoimmunotherapy, 9.4 months with platinum-based chemotherapy, and 3.6 months with non-platinum chemotherapy (P < .001). Median PFS was 5.3 months, 5.6 months, and 2.6 months, respectively (P < .001).
Compared with platinum-based chemotherapy, chemoimmunotherapy significantly reduced the risk of death (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62 to 0.87; P < .001) and disease progression (HR, 0.79; 95% CI, 0.67 to 0.93; P = .006). Non-platinum chemotherapy was associated with more than double the risk of death (HR, 2.19; 95% CI, 1.84 to 2.61; P < .001) and disease progression (HR, 2.28; 95% CI, 1.91 to 2.72; P < .001).
Thoracic radiotherapy was independently associated with improved OS (HR, 0.57; 95% CI, 0.48 to 0.69; P < .001) and PFS (HR, 0.59; 95% CI, 0.49 to 0.70; P < .001). Although baseline brain metastases were not independently associated with prognosis, brain radiotherapy among patients with brain metastases significantly improved OS (HR, 0.47; 95% CI, 0.35 to 0.65; P < .001).
Immune-related adverse events were reported in 21.67% patients treated with chemoimmunotherapy and led to 28 treatment discontinuations. Immune-related adverse events were independently associated with longer OS (HR, 0.67; 95% CI, 0.46 to 0.97; P = .032) and PFS (HR, 0.68; 95% CI, 0.47 to 0.95; P = .035). Discontinuation of immunotherapy due to immune-related adverse events did not compromise survival outcomes.
“Chemoimmunotherapy confers a clear OS advantage over conventional chemotherapy in real-world ES-SCLC,” concluded Dr Dimitriou et al. “Our results further highlight the critical importance of multimodal treatments, including brain and thoracic radiotherapy, in further enhancing patient outcomes.”
Source:
Dimitriou K, Shi S, Marginenau A, et al. Chemoimmunotherapy versus chemotherapy for extensive-stage small cell lung cancer in the real-world setting: Retrospective study of 904 patients. Clin Lung Cancer. Published online: June 23, 2026. doi: 10.1016/j.cllc.2026.06.004
